There is a growing temptation in healthcare AI to assume that once a dataset is large, digitised and structurally tidy, it is ready for deployment. It is not. Recent cardiovascular AI literature is increasingly explicit that large datasets can still be limited by measurement noise, systematic missing-ness, site-specific batch effects, annotation error, sampling bias and temporal drift. In other words, “AI-ready” often means only that data are available, not that they are trustworthy.
This distinction matters because machine learning systems are exquisitely sensitive to flaws in the data they inherit. Best-practice guidance for AI-enabled tests in cardiology recommends strict separation of training and testing data, careful cohort selection and comparison with appropriate non-ML reference models. These are not academic niceties; they are safeguards against over-claiming performance and underestimating real-world error. If validation is weak, the apparent intelligence of a model can simply reflect leakage, bias or overfitting.
Cardiovascular imaging adds further complexity. The 2025 ASE reporting standard emphasises that AI integration depends on consistent, organised imaging data, while contemporary implementation papers in cardiology continue to flag data quality, labelling accuracy and bias as major barriers to safe adoption. This means validation must examine more than headline accuracy. It should test portability across sites, subgroups, equipment, disease prevalence and changing clinical workflows. A model that performs well in one curated dataset may fail when exposed to different scanners, different operators or different populations.
The deeper point is simple. Validation is what converts technical promise into clinical credibility. AI is not made trustworthy by scale alone; it becomes trustworthy when data provenance is clear, labels are defensible, performance is stress-tested and outputs are monitored in practice. In healthcare, “good enough for development” is not the same as good enough for patients.
